MedTrace Logo

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

NCT00695877 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-11-01

No results posted yet for this study

Summary

Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response. The purpose of this study is to determine the safety of and immune response to an adenovirus serotype HIV vaccine in HIV uninfected adults.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

Ad5.ENVA.48 HIV-1 vaccine

Recombinant adenovirus serotype 5 HIV-1 vaccine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Lindsey Baden, MD · Brigham and Women's Hospital

  • Dan Barouch, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-08
Primary Completion
2012-12-11
Completion
2016-10-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00695877 on ClinicalTrials.gov